StoxEmcure Pharmaceuticals vs Narayana Hrudayalaya: share price & financials comparison
NSE: EMCURE vs NH · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Emcure Pharmaceuticals vs Narayana Hrudayalaya at a glance
Emcure Pharmaceuticals (EMCURE) has a market capitalisation of ₹41,979 Cr, against ₹38,890 Cr for Narayana Hrudayalaya (NH). Over the past year Emcure Pharmaceuticals has returned +65.2%, compared with +5.7% for Narayana Hrudayalaya. On valuation, Emcure Pharmaceuticals trades at a lower P/E of 38.4 versus 45.3. Emcure Pharmaceuticals earns a higher return on equity (20.5% vs 17.2%). Emcure Pharmaceuticals comes out ahead on size, profitability, financial health, momentum and technicals. Narayana Hrudayalaya comes out ahead on valuation. Across the scored metrics below, Emcure Pharmaceuticals leads on 11 and Narayana Hrudayalaya on 3. On StoxGud's 10-point checklist, Emcure Pharmaceuticals scores 9/10 and Narayana Hrudayalaya scores 7/10.
| Metric | Emcure Pharmaceuticals | Narayana Hrudayalaya |
|---|---|---|
| Size | ||
| Market cap | ₹41,979 Cr | ₹38,890 Cr |
| Revenue (latest FY) | ₹9,204 Cr | ₹7,896 Cr |
| Net profit (latest FY) | ₹924 Cr | ₹806 Cr |
| Valuation | ||
| P/E | 38.4 | 45.3 |
| P/B | 7.86 | 7.77 |
| Dividend yield | 0.14% | 0.23% |
| Profitability | ||
| Return on equity | 20.5% | 17.2% |
| Net profit margin | 10.7% | 8.4% |
| Operating margin | 20.4% | 18.5% |
| Growth | ||
| Revenue growth (YoY) | +24.3% | +73.0% |
| Net profit growth (YoY) | +33.7% | +16.5% |
| Revenue CAGR (multi-year) | — | +25.0% |
| Financial health | ||
| Debt to equity | 0.27 | 0.99 |
| Momentum | ||
| 1-month return | +15.4% | +10.4% |
| 1-year return | +65.2% | +5.7% |
| 3-year CAGR | — | +22.4% |
| 5-year CAGR | — | +28.5% |
| 10-year CAGR | — | +18.7% |
| Distance from 52W high | -1.4% | -8.5% |
| Technicals | ||
| RSI (14) | 81 | 71 |
| Price vs 200-day avg | +27.3% | +3.6% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Emcure Pharmaceuticals | Narayana Hrudayalaya |
|---|---|---|
| Price above 50-day average | ✓ | ✓ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✗ |
| RSI in healthy 40–70 zone | ✗ | ✗ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✓ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✓ | ✓ |
| Net profit margin above 10% | ✓ | ✗ |
| P/E below industry median | ✓ | ✓ |
| Score | 9/10 | 7/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Emcure Pharmaceuticals or Narayana Hrudayalaya?
Emcure Pharmaceuticals has a market cap of ₹41,979 Cr and Narayana Hrudayalaya has a market cap of ₹38,890 Cr as of 06 Nov 2026.
Which has a lower P/E, Emcure Pharmaceuticals or Narayana Hrudayalaya?
Emcure Pharmaceuticals has the lower P/E: Emcure Pharmaceuticals trades at 38.4 and Narayana Hrudayalaya at 45.3.
Which gave better returns in the last year, Emcure Pharmaceuticals or Narayana Hrudayalaya?
Emcure Pharmaceuticals did better: Emcure Pharmaceuticals returned +65.2% and Narayana Hrudayalaya returned +5.7% over one year.
Is Emcure Pharmaceuticals or Narayana Hrudayalaya a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Emcure Pharmaceuticals scores 9/10 and Narayana Hrudayalaya scores 7/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.